GlassScriptPhysician profile
David M Hardin
NPI 1629489059
$2,296.29
in general payments reported to CMS, 2019-2025
19 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.05 · 2021: $81.80 · 2022: $717 · 2023: $780 · 2024: $500 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $877.00 | 2022-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.25 | 2021-2023 | Relistor |
| Braeburn INC. | $286.79 | 2023-2025 | Brixadi |
| Indivior INC. | $268.94 | 2022-2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $121.23 | 2022-2024 | Xtampza |
| Ibsa Pharma INC. | $54.56 | 2022-2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $41.67 | 2022 | |
| Grt US Holding, INC. | $41.52 | 2022 | |
| Genentech USA, INC. | $38.76 | 2021 | |
| Abbott Laboratories | $33.85 | 2024 | Proclaim |
| Boston Scientific Corporation | $31.87 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Orexo US, INC. | $28.10 | 2020-2024 | Zubsolv |
| Novo Nordisk INC | $19.33 | 2023 | |
| Pfizer INC. | $18.00 | 2023 | |
| Dexcom, INC. | $16.23 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.71 | 2020 | |
| Forte Bio-Pharma LLC | $13.88 | 2020 | |
| Hikma Pharmaceuticals USA | $12.56 | 2022 | |
| Redhill Biopharma INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.